Protocol Ledger

NCT03789656 · Phase II · COMPLETED

An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)

Interventional Phase II clinical trial protocol NCT03789656 sponsored by Crinetics Pharmaceuticals in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-03-12 Enrollment: 47 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03789656
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)47 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03789656
Protocol FieldVerified Registry Value
NCT IdentifierNCT03789656
Consolidated Lead SponsorCrinetics Pharmaceuticals
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment47 participants (ACTUAL)
Registered Start Date2019-03-12
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI